Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2003 Dicembre;47(4) > The Quarterly Journal of Nuclear Medicine 2003 Dicembre;47(4):279-91

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2003 Dicembre;47(4):279-91

USE OF RADIOLABELLED PEPTIDES FOR SCINTIGRAPHY IN NON-ONCOLOGIC DISEASES 

Non-oncologic applications of radiolabeled peptides in nuclear medicine

Knight L. C.

Nuclear Medicine Division Department of Diagnostic Imaging Temple University School of Medicine, Philadelphia, PA, USA

Radiolabeled pep­tides ­have ­been inves­ti­gat­ed for diag­nos­tic imag­ing in a varie­ty of non­on­co­log­ic dis­eas­es. For imag­ing throm­boem­bol­ic dis­ease, pep­tides ­which ­bind to var­i­ous com­po­nents of throm­bi ­have ­been test­ed. For tar­get­ing the ­fibrin com­po­nent of throm­bi, pep­tide ana­logues of ­fibrin or frag­ments of fibro­nec­tin ­which ­have a dis­tinct bind­ing ­domain for ­fibrin ­have ­been stud­ied. For tar­get­ing acti­vat­ed plate­lets with­in throm­bi, lin­e­ar and ­cyclic pep­tide antag­o­nists of the gly­co­pro­tein IIb/IIIa recep­tor on plate­lets ­have ­been stud­ied, as ­well as nat­u­ral­ly occur­ring antag­o­nists of ­this recep­tor ­which are ­found in ven­oms. Analogues of lam­i­nin and throm­bos­pon­din ­which ­bind to oth­er recep­tors on plate­lets ­have ­also ­been test­ed. There is an ­approach ­which ­uses a pep­tide to tar­get throm­bin ­which is seques­tered with­in a ­fibrin ­clot. Another ­area of inves­ti­ga­tion has ­been to devel­op an ­improved radio­phar­ma­ceu­ti­cal for imag­ing ­sites of infec­tion and/or inflam­ma­tion. Peptides ­which ­would ­bind to leu­ko­cytes in ­vivo, ­such as antag­o­nists to the tuft­sin recep­tor, chem­o­tac­tic pep­tides, inter­leu­kin-8, or a plate­let fac­tor 4 ana­logue, ­have ­been radio­lab­eled for ­this pur­pose. These ­agents ­would ­enable imag­ing of ­both infec­tion and inflam­ma­tion. Development of a radio­phar­ma­ceu­ti­cal for spe­cif­i­cal­ly imag­ing infec­tion has ­focused on anti­mi­cro­bi­al pep­tides ­such as ­human neu­troph­il defen­sin, ubi­qui­ci­din, ­human lac­to­fer­rin and ala­fos­fal­in, ­which are expect­ed to ­bind selec­tive­ly to micro­or­gan­isms and not to leu­ko­cytes. Radiolabeled pep­tides are ­also ­being ­explored as ­agents for assess­ing ­unstable ath­e­ros­cle­rot­ic ­plaque (endo­the­lin), amy­loid depos­its (amy­loid β pep­tides), and the con­se­quenc­es of dia­betes mel­lit­us (human C-pep­tide).

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina